Veradermics, Incorporated (MANE) Financials

Key financial figures for Veradermics, Incorporated (Q2 2026).

Veradermics, Incorporated reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $23.5 million, or -$0.58 per share. Free cash flow for the period was -$14.5 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Veradermics, Incorporated are on the SentiSense financials page.

Revenue
$0
Net Income
-$24M
EPS
$-0.58
Total Assets
$826M
Operating Cash Flow
-$14M

Recent quarters

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
Q2 FY2026$0-$24M-$0.58-$15M
Q1 FY2026$0-$27M-$0.80-$21M
Q4 FY2025$0-$22M-$0.76-$24M
Q3 FY2025$0-$20M-$0.64-$19M
Q2 FY2025$0-$16M-$0.51-$16M

Recent fiscal years

PeriodRevenueNet IncomeEPSOperating MarginFree Cash Flow
FY2025$0-$70M-$2.38-$72M
FY2024$0-$26M-$0.14-$24M
FY2023$0-$16M-$0.08-$14M

Frequently asked questions

What was Veradermics, Incorporated's revenue last quarter?

Veradermics, Incorporated reported revenue of $0.00 for Q2 FY2026.

Is Veradermics, Incorporated profitable?

Not in its most recent reported period. Veradermics, Incorporated reported a net loss of $23.5 million for Q2 FY2026.

How much free cash flow did Veradermics, Incorporated generate?

Veradermics, Incorporated generated free cash flow of -$14.5 million in Q2 FY2026, after capital expenditure.

Full income statement, balance sheet and cash flow for Veradermics, Incorporated on SentiSense, with up to forty quarters and twenty fiscal years of history.